ACE-041: Interim Phase I data

Interim data from an ongoing, dose-escalation Phase I trial in 19 evaluable patients showed that subcutaneous 0.1-1.6 mg/kg ACE-041 every 3 weeks produced 1 partial response and 3 cases of stable dise...